The DOVE Study: Determining Effects of Platelet Inhibition on Vaso-occlusive Events
Assess the efficacy of prasugrel compared to placebo in pediatric patients with sickle cell disease as measured by reductions in the rate of vaso-occlusive crisis throughout the study.
SCD patients, 2 to 17 years old with hemoglobin SS or Sβ0 have had at least two episodes of VOC in the past year. If patients are taking hydroxyurea, they must be on a stable dose for the 60 days prior to randomization.
PI: Dr. Kim Smith-Whitley
SC: Tannoa Jackson, Henrietta Enninful–Eghan
Sponsor: Eli Lilly and Company